首页> 外文期刊>Oncology letters >Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma
【24h】

Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma

机译:血清中学素在预测恶性胸膜间皮瘤患者存活中的潜在作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting the course of the disease and prognosis. The aim of the present study was to highlight the prognostic significance of serum soluble mesothelin-related protein (Se-SMRP) in patients with MPM at diagnosis. Se-SMRP was determined in 60 patients using an ELISA commercial kit. Se-SMRP levels were subdivided into three tertile-based categories and in each category overall survival (OS) indexes were determined using the Kaplan-Meier and Cox regression analyses. The association between Se-SMRP levels and OS was also assessed by restricted cubic spline (RCS) analysis. No notable differences in the Kaplan-Meier probabilities were identified across the Se-SMRP categories ( 1.46 nM) although an upward trend in death rate ratios (RR) was pointed out by comparing the higher (RR=1.95) and intermediate (RR=1.86) categories with the lower category (RR=1.00). In addition, such an increasing tendency, particularly when the biomarker exceeded 1.0 nM, was confirmed by an RCS function of Se-SMPR levels fitted to survival data using the Cox regression equation. The present study provided evidence in favor of a prognostic value of Se-SMRP in patients with MPM.
机译:恶性胸膜间皮瘤(MPM)是一种侵袭性肿瘤,生存率低。因此,有有效的生物标志物预测疾病的病程和预后至关重要。本研究的目的是强调血清可溶性间皮素相关蛋白(Se SMRP)在MPM患者诊断时的预后意义。使用ELISA商业试剂盒对60名患者进行Se SMRP检测。Se SMRP水平被细分为三个三分位数的类别,在每个类别中,使用Kaplan-Meier和Cox回归分析确定总生存率(OS)指数。通过限制性三次样条(RCS)分析评估Se SMRP水平与OS之间的相关性。尽管通过比较较高(RR=1.95)和中等(RR=1.86)类别与较低类别(RR=1.00)的死亡率比(RR)有上升趋势,但Se SMRP类别(1.46 nM)的Kaplan-Meier概率没有显著差异。此外,这种增加趋势,尤其是当生物标志物超过1.0nm时,通过使用Cox回归方程拟合生存数据的Se SMPR水平的RCS函数得到证实。本研究提供了支持Se SMRP对MPM患者预后价值的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号